Deletions or losses in chromosomes 5 or 7 are recurrent nonrandom abnormalities in acute myeloid leukemia (AML), and are associated with prior exposure to carcinogens or leukemogenic agents, and with poor prognosis. Their occurrence and significance in adult acute lymphocytic leukemia (ALL) is not well described. The aim of the study was to evaluate the incidence, associations and implications of chromosome 5 or 7 abnormalities in adult ALL. Patients with newly diagnosed ALL referred to MD Anderson Cancer Center between 1980 and 1996 were analyzed. Characteristics and outcome of patients with or without chromosome 5 or 7 abnormalities were compared by standard statistical methods. Thirty-one of 468 patients (6.6%) had chromosome 5 or 7 abnormalities. Loss of chromosome 5 occurred in six cases, three of them had both chromosome 5 and 7 abnormalities. Deletion or loss of chromosome 7 occurred as a single abnormality in three patients; in 28 patients it was associated with other abnormalities. The most significant cytogenetic association was with the Philadelphia chromosome (Ph) abnormality occurring in nine patients (29%). Compared with patients without the abnormalities, patients with chromosome 5 or 7 abnormalities tended to express CD34 more frequently (74% vs 54% P = 0.07), to be older (age Ͼ60 years 29% vs 18% P = 0.14), and to be associated with Ph (29% vs 11% P = 0.004). With therapy, the complete response (CR) rate with chromosome 5 or 7 abnormalities was lower (64% vs 79% P = 0.038) but the survival rate was similar (3-year survival rate 32% vs 36% P = 0.14). When the 22 patients without Ph were considered separately, the CR and survival rates were similar among patients with or without chromosome 5 or 7 abnormalities. Abnormalities in chromosome 5 or 7 are not specific for AML, and may occur in ALL. Unlike in AML, chromosome 5 or 7 abnormalities in ALL were not predictive of worse prognosis, which is accounted for mostly by the association with Ph.
Introduction
Cytogenetic studies in de novo acute leukemia have identified nonrandom chromosomal abnormalities to be associated with significant differences in patient prognosis. Deletions or losses in chromosomes 5 or 7, alone or with other changes, have been found in a variety of hematological disorders, including acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS), and are associated with prior exposure to carcinogens and with poor prognosis. [1] [2] [3] [4] [5] [6] Little is known about the prognostic significance of chromosome 5 or 7 abnormalities in ALL. Their presence may intuitively imply poor prognosis, as suggested by their prognostic effect in AML and MDS. However, such prognostic associations have not been described in ALL. Herein, we report on the incidence and implications of chromosome 5 or 7 abnormalities in adult ALL.
Materials and methods

Study group
Four hundred and sixty-eight patients with newly diagnosed untreated ALL, 15 years and older, who were referred to our institution between 1980 and 1996, were reviewed. The Insti- tutional Review Board approved the studies at MD Anderson Cancer Center. Samples were obtained with the informed consent of patients. The diagnosis was based on morphological analysis of bone marrow aspirates and biopsies according to the French-American-British (FAB) guidelines. 7 Bone marrow specimens were evaluated using cytochemical staining procedures including myeloperoxidase (MPO), terminal deoxynucleotidyl transferase (TdT), non-specific esterase, and periodic-acid schiff (PAS). The diagnostic evaluations were complemented by immunophenotypic and flow cytometric studies. The cut-off point for positivity was at 20%. ALL was diagnosed if blasts were morphologically lymphoid, TdT-positive, MPO-negative, and were positive for lymphoid markers. Cytogenetic techniques utilized on the bone marrow and peripheral blood have been previously described. 8 Karyotypic classification was according to the International System for Human Cytogenetic Nomenclature (ISCN). 9 
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Statistical methods
Survival was estimated by the method of Kaplan and Meier. 10 Differences in survival curves were analyzed by the log rank test. 11 Variables were compared by chi-square tests.
Results
Characteristics of patients with chromosomes 5 or 7 abnormalities
Thirty-one of 468 patients analyzed (6.6%) had abnormalities of chromosomes 5 or 7. Compared with patients not exhibiting the changes, patients with chromosome 5 or 7 abnormalities did not have significantly different characteristics, except for a trend for older age (age у60 years 29% vs 18%, P = 0.14) ( Table 1) .
Phenotypic and cytogenetic characteristics
Among patients who had imunophenotypic analysis, positive expression of CD10 (CALLA) was detected in 17 of 24 patients analyzed (70%), positive expression of CD19 in 15 of 20 patients (75%) and positive expression of T cell markers (CD2, CD5, CD7) in five patients (21%). Myeloid marker positivity (CD13, CD14, CD33) was found in 12 of 23 patients (52%). Compared with patients without chromosome 5 or 7 abnormalities, these patients had more frequent expression of CD34 positivity (17 of 23 patients = 74% vs 54%, P = 0.07; Table 2 ). Cytogenetic abnormalities detected in the 31 patients were deletion in chromosome 7 in seven patients, loss of chromosome 7 in 19 patients, and both abnormalities occurred in two patients. Loss of chromosome 5 was found in six cases; three of them had both chromosome 5 and 7 abnormalities. Three patients had deletion of chromosome 7 as the sole abnormality. The remaining 28 had other chromosomal abnormalities, the most significant being the presence of the Philadelphia chromosome (Ph) in nine patients (29%). The incidence of this association was higher than in patients without chromosome 5 or 7 abnormalities (29% vs 11%, P = 0.004). The detailed chromosomal abnormalities associated with chromosome 5 or 7 abnormalities among the 31 patients are shown in Table 3 .
Response and survival
The complete remission (CR) rate was 64% among patients with chromosomes 5 or 7 abnormalities vs 79% for other ALL patients (P = 0.038). The estimated 3-year survival rate was 32% vs 36% (P = 0.14) (Figure 1 ). When Ph-positive cases were excluded, the CR rates were comparable among patients with or without chromosome 5 or 7 abnormalities (68% vs 81% P = 0.11), and the estimated 3-year survival rates were similar (36%) (Figure 2 ).
Discussion
Since chromosome 5 or 7 abnormalities predominantly affect the myeloid lineage, it has been assumed, in suspicious morphology instances, that they would favor myeloid rather than lymphoid lineage, and would implicate poor prognosis. However, they have been also rarely described in lymphoid disorders. 12, 13 Van den Berghe and Michaux 12 reported 5q− as a sole anomaly in six of 52 cases with B cell ALL, and in two of 10 cases with T cell ALL. Deletion of 7q was also reported in association with chronic lymphoid malignancy. 13 Little is known about the significance of chromosome 5 or 7 abnormalities in ALL 14, 15 where chromosomal abnormalities have a major prognostic impact. 16 This study attempted to define the associations of chromosome 5 or 7 abnormalities in adult ALL, in relation to host and disease features, and to prognosis. In our analysis in adults with ALL, no significant differences were found between patients with and without chromosomes 5 or 7 abnormalities with regard to clinical or hematologic features (Table 1 ). There was a tendency for patients with chromosome 5 or 7 abnormalities to be older and to express CD34 more often. They had also a significant association with Ph (P = 0.004). The CR rate with chromosome 5 or 7 abnormalities was lower than that of adult ALL patients without these abnormalities (64% vs 79%; P = 0.038), but the estimated 3-year survival rates were not statistically different (32% vs 36% P = 0.14) (Figure 1) . When the nine patients who had both chromosome 5 or 7 abnormalities and Ph were excluded, the CR rate of the remaining 22 with chromosome 5 or 7 abnormalities was comparable to adult ALL without these abnormalities (68% vs 81%, P = 0.11) and the estimated 3-year survival rates were similar (Figure 2) . In summary, chromosome 5 or 7 abnormalities can be associated with ALL, and should not be used as a diagnostic clue for AML in ambiguous cases. In contrast to what was observed with myeloid malignancies, they were not associated with poor prognosis in ALL, except when occurring together with Ph.
